Michelle Kelliher

2 months ago | nature.com | Shahid Banday |Alok Mishra |Tianyi Ye |Junhui Li |Jason T. Yustein |Michelle Kelliher | +2 more

AbstractEwing sarcoma (ES) is an aggressive bone cancer driven by the oncogenic fusion-protein EWSR1::FLI1, which is not present in normal cells and is therefore an attractive therapeutic target. However, as a transcription factor, EWSR1::FLI1 is considered undruggable. Factors that promote EWSR1::FLI1 expression, and thus whose inhibition would reduce EWSR1::FLI1 protein levels and function, are potential drug targets.